Physician profile
Alka A Singh
NPI 1568605038
$4,477.75
in general payments reported to CMS, 2019-2025
21 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $392 · 2021: $343 · 2022: $1,082 · 2023: $1,172 · 2024: $753 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $632.03 | 2020-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $515.62 | 2020-2025 | Tezspire, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $513.01 | 2022-2024 | |
| Glaxosmithkline, LLC. | $499.42 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $494.90 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $478.01 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.67 | 2020-2025 | Xifaxan |
| Abbott Laboratories | $263.22 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $251.27 | 2022-2023 | Xarelto, Spravato |
| Horizon Therapeutics Plc | $110.51 | 2019-2021 | |
| Mylan Specialty L.P. | $91.59 | 2020 | |
| Shield Therapeutics INC | $49.87 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.86 | 2020-2023 | Jardiance |
| Pfizer INC. | $43.18 | 2022-2025 | |
| Astellas Pharma US INC | $34.39 | 2024 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.90 | 2019-2021 | |
| Heartflow, INC. | $32.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.00 | 2024 | Voquezna |
| Dexcom, INC. | $24.21 | 2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $21.75 | 2025 | Licart, Flector, Tirosint |
| E.R. Squibb & Sons, L.L.C. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.